Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar
Go back to Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar| (NASDAQ: SVRA) | Delayed: 5.69 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.69 | 52 Week High | $ | |||
| Open | $5.69 | 52 Week Low | $ | |||
| Day High | $5.69 | P/E | N/A | |||
| Day Low | $5.69 | EPS | $ | |||
| Volume | 4,346 | |||||
